Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor

Journal of Immunology

Volumn 177, Issue 2, 2006, Pages 1152-1159

  Ibáñez, Anna ^a   Sarrias, Maria Rosa ^a   Farnós, Montserrat ^a   Gimferrer, Idoia ^a   Serra Pagès, Carles ^a   Vives, Jordi ^a   Lozano, Francisco ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD3 ANTIGEN; CD6 ANTIGEN; CHIMERIC PROTEIN; LYMPHOCYTE MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; STRESS ACTIVATED PROTEIN KINASE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CELL MATURATION; CELL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIGAND BINDING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REPORTER GENE; SERUM RESPONSIVE ELEMENT; T LYMPHOCYTE; THYMOCYTE; TRANSCRIPTION INITIATION;

EID: 33745853524     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.2.1152     Document Type: Article

References (51)

1. Bowen, M. A., A. A. Aruffo, and J. Bajorath. 2000. Cell surface receptors and their ligands: in vitro analysis of CD6-CD166 interactions. Proteins 40: 420-428.
2. Aruffo, A., M. A. Bowen, D. D. Patel, B. F. Haynes, G. C. Starling, J. A. Gebe, and J. Bajorath. 1997. CD6-ligand interactions: a paradigm for SRCR domain function? Immunol. Today 18: 498-504.
3. Aruffo, A., M. B. Melnick, P. S. Linsley, and B. Seed. 1991. The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins. J. Exp. Med, 174: 949-952.
4. Sarrias, M. R., J. Gronlund, O. Padilla, J. Madsen, U. Holmskov, and F. Lozano. 2004. The scavenger receptor cysteine-rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system. Crit. Rev. Immunol. 24: 1-37.
5. Bowen, M. A., J. Bajorath, A. W. Siadak, B. Modrell, A. R. Malacko, H. Marquardt, S. G. Nadler, and A. Aruffo. 1996. The amino-terminal immunoglobulin-like domain of activated leukocyte cell adhesion molecule binds specifically to the membrane-proximal scavenger receptor cysteine-rich domain of CD6 with a 1:1 stoichiometry. J. Biol. Chem. 271: 17390-17396.
6. Bowen, M. A., D. D. Patel, X. Li, B. Modrell, A. R. Malacko, W. C. Wang, H. Marquardt, M. Neubauer, J. M. Pesando, U. Francke, et al. 1995. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand J. Exp. Med. 181: 2213-2220.
7. Patel, D. D., S. F. Wee, L. P. Whichard, M. A. Bowen, J. M. Pesando, A. Aruffo, and B. F. Haynes. 1995. Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells. J. Exp. Med. 181: 1563-1568.
8. Whitney, G. S., G. C. Starling, M. A. Bowen, B. Modrell, A. W. Siadak, and A. Aruffo. 1995. The membrane-proximal scavenger receptor cysteine-rich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site. J. Biol. Chem. 270: 18187-18190.
9. Singer, N. G., D. A. Fox, T. M. Haqqi, L. Beretta, J. S. Endres, S. Prohaska, J. R. Parties, J. Bromberg, and R. M. Sramkoski. 2002. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. Int. Immunol. 14: 585-597.
10. Cortes, F., F. Deschaseaux, N. Uchida, M. C. Labastie, A. M. Friera, D. He, P. Charbord, and B. Peault. 1999. HCA, an immunoglobulin-like adhesion molecule present on the earliest human hematopoietic precursor cells, is also expressed by stromal cells in blood-forming tissues. Blood 93: 826-837.
11. Ohneda, O., K. Ohneda, F. Arai, J. Lee, T. Miyamoto, Y. Fukushima, D. Dowbenko, L. A. Lasky, and T. Suda. 2001. ALCAM (CD166): its role in hematopoietic and endothelial development. Blood 98: 2134-2142.
12. Saifullah, M. K., D. A. Fox, S. Sarkar, S. M. Abidi, J. Endres, J. Piktel, T. M. Haqqi, and N. G. Singer. 2004. Expression and characterization of a novel CD6 ligand in cells derived from joint and epithelial tissues. J. Immunol. 173: 6125-6133.
13. Morimoto, C., C. E. Rudd, N. L. Letvin, M. Hagan, and S. F. Schlossman. 1988. 2H1 - a novel antigen involved in T lymphocyte triggering. J. Immunol. 140: 2165-2170.
14. Gangemi, R. M., J. A. Swack, D. M. Gaviria, and P. L. Romain. 1989. Anti-T12, an anti-CD6 monoclonal antibody, can activate human T lymphocytes. J. Immunol. 143: 2439-2447.
15. Swack, J. A., R. M. Gangemi, C. E. Rudd, C. Morimoto, S. F. Schlossman, and P. L. Romain. 1989. Structural characterization of CD6: properties of two distinct epitopes involved in T cell activation. Mol. Immunol. 26: 1037-1049.
16. Bott, C. M., J. B. Doshi, C. Morimoto, P. L. Romain, and D. A. Fox. 1993. Activation of human T cells through CD6: functional effects of a novel anti-CD6 monoclonal antibody and definition of four epitopes of the CD6 glycoprotein. Int. Immunol. 5: 783-792.
17. Osorio, L. M., C. A. Garcia, M. Jondal, and S. C. Chow. 1994. The anti-CD6 mAb, IOR-T1, defined a new epitope on the human CD6 molecule that induces greater responsiveness in T cell receptor/CD3-mediated T cell proliferation. Cell. Immunol. 154: 123-133.
18. Osorio, L. M., M. Rottenberg, M. Jondal, and S. C. Chow. 1998. Simultaneous cross-linking of CD6 and CD28 induces cell proliferation in resting T cells. Immunology 93: 358-365.
19. Singer, N. G., B. C. Richardson, D. Powers, F. Hooper, F. Lialios, J. Endres, C. M. Bott, and D. A. Fox. 1996. Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes. Immunology 88: 537-543.
20. Gimferrer, I., M. Calvo, M. Mittelbrunn, M. Farnos, M. R. Sarrias, C. Enrich, J. Vives, F. Sanchez-Madrid, and F. Lozano. 2004. Relevance of CD6-mediated interactions in T cell activation and proliferation. J. Immunol. 173: 2262-2270.
21. Gimferrer, I., M. Famos, M. Calvo, M. Mittelbrunn, C. Enrich, F. Sanchez-Madrid, J. Vives, and F. Lozano. 2003. The accessory molecules CD5 and CD6 associate on the membrane of lymphoid T cells. J. Biol. Chem. 278: 8564-8571.
22. Zimmerman, A. W., B. Joosten, R. Torensma, J. R. Parnes, F. N. van Leeuwen, and C. G. Figdor. 2006. Long-term engagement of CD6 and ALCAM is essential for T cell proliferation induced by dendritic cells. Blood 107: 3212-3220.
23. Hassan, N. J., A. N. Barclay, and M. H. Brown. 2004. Frontline: optimal T cell activation requires the engagement of CD6 and CD166. Eur. J. Immunol. 34: 930-940.
24. Osorio, L. M., A. De Santiago, M. Aguilar-Santelises, H. Mellstedt, and M. Jondal. 1997. CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Blood 89: 2833-2841.
25. Robinson, W. H., H. E. Neuman de Vegvar, S. S. Prohaska, J. W. Rhee, and J. R. Parnes. 1995. Human CD6 possesses a large, alternatively spliced cytoplasmic domain. Eur. J. Immunol. 25: 2765-2769.
26. Cardenas, L., A. C. Carrera, E. Yague, R. Pulido, F. Sanchez-Madrid, and M. O. de Landazuri. 1990. Phosphorylation-dephosphorylation of the CD6 glycoprotein renders two isoforms of 130 and 105 kilodaltons. Effect of serum and protein kinase C activators. J. Immunol. 145: 1450-1455.
27. Wee, S., G. L. Schieven, J. M. Kirihara, T. T. Tsu, J. A. Ledbetter, and A. Aruffo. 1993. Tyrosine phosphorylation of CD6 by stimulation of CD3: augmentation by the CD4 and CD2 coreceptors. J. Exp. Med. 177: 219-223.
28. Kobarg, J., G. S. Whitney, D. Palmer, A. Aruffo, and M. A. Bowen. 1997. Analysis of the tyrosine phosphorylation and calcium fluxing of human CD6 isoforms with different cytoplasmatic domains. Eur. J. Immunol. 27: 2971-2980.
29. Osorio, L. M., C. Ordonez, C. A. Garcia, M. Jondal, and S. C. Chow. 1995. Evidence for protein tyrosine kinase involvement in CD6-induced T cell proliferation. Cell. Immunol. 166: 44-52.
30. Gimferrer, I., A. Ibanez, M. Farnos, M. R. Sarrias, R. Fenutria, S. Rosello, P. Zimmermann, G. David, J. Vives, C. Serra-Pages, and F. Lozano. 2005. The lymphocyte receptor CD6 interacts with syntenin-1, a scaffolding protein containing PDZ domains. J. Immunol. 175: 1406-1414.
31. Dong, C., R. J. Davis, and R. A. Flavell. 2002. MAP kinases in the immune response. Annu. Rev. Immunol. 20: 55-72.
32. Simarro, M., C. Pelassy, J. Calvo, L. Places, C. Aussel, and F. Lozano. 1997. The cytoplasmic domain of CD5 mediates both TCR/CD3-dependent and -independent diacylglycerol production. J. Immunol. 159: 4307-4315.
33. Pedraza-Alva, G., L. B. Merida, S. J. Burakoff, and Y. Rosenstein. 1998. T cell activation through the CD43 molecule leads to Vav tyrosine phosphorylation and mitogen-activated protein kinase pathway activation. J. Biol. Chem. 273: 14218-14224.
34. Beltman, J., J. R. Erickson, G. A. Martin, J. F. Lyons, and S. J. Cook. 1999. C3 toxin activates the stress signaling pathways, JNK and p38, but antagonizes the activation of AP-1 in rat-1 cells. J. Biol. Chem. 274: 3772-3780.
35. Lee, D. M. 1998. CD166 workshop: investigation of the role of CD6 and CD6 ligand in proliferative responses and cytokine production in human peripheral blood mononuclear cells. In Leucocyte Typing VI: White Cell Differentiation Antigens. T. Kishimoto, H. Kikutani, A. E. G. K. Von dem Borne, S. M. Goyert, D. Mason, M. Miyasaka, L. Moretta, K. Okumura, S. Shaw, T. A. Springer, et al., eds. Garland Publishing, New York, p. 464-465.
36. Straus, D. B., and A. Weiss. 1992. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 70: 585-593.
37. Gille, H., M. Kortenjann, O. Thomae, C. Moomaw, C. Slaughter, M. H. Cobb, and P. E. Shaw. 1995. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J. 14: 951-962.
38. Rincon, M., R. A. Flavell, and R. A. Davis. 2000. The JNK and P38 MAP kinase signaling pathways in T cell-mediated immune responses. Free Radical Biol. Med. 28: 1328-1337.
39. Gupta, S. K., and J. P. Singh. 1994. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J. Cell Biol. 127: 1121-1127.
40. Castro, M. A., R. J. Nunes, M. I. Oliveira, P. A. Tavares, C. Simoes, J. R. Parnes, A. Moreira, and A. M. Carmo. 2003. OX52 is the rat homologue of CD6: evidence for an effector function in the regulation of CD5 phosphorylation. J. Leukocyte Biol. 73: 183-190.
41. Sunder-Plassmann, R., and E. L. Reinherz. 1998. A p56lck-independent pathway of CD2 signaling involves Jun kinase. J. Biol. Chem. 273: 24249-24257.
42. Schade, A. E., and A. D. Levine. 2004. Cutting edge: extracellular signal-regulated kinases 1/2 function as integrators of TCR signal strength. J. Immunol. 172: 5828-5832.
43. Rincon, M., R. A. Flavell, and R. J. Davis. 2001. Signal transduction by MAP kinases in T lymphocytes. Oncogene 20: 2490-2497.
44. Crompton, T., K. C. Gilmour, and M. J. Owen. 1996. The MAP kinase pathway controls differentiation from double-negative to double-positive thymocyte. Cell 86: 243-251.
45. Diehl, N. L., H. Enslen, K. A. Fortner, C. Merritt, N. Stetson, C. Charland, R. A. Flavell, R. J. Davis, and M. Rincon. 2000. Activation of the p38 mitogen-activated protein kinase pathway arrests cell cycle progression and differentiation of immature thymocytes in vivo. J. Exp. Med. 191: 321-334.
46. Alberola-Ila, J., K. A. Forbush, R. Seger, E. G. Krebs, and R. M. Perlmutter. 1995. Selective requirement for MAP kinase activation in thymocyte differentiation. Nature 373: 620-623.
47. Alberola-Ila, J., K. A. Hogquist, K. A. Swan, M. J. Bevan, and R. M. Perlmutter. 1996. Positive and negative selection invoke distinct signaling pathways. J. Exp. Med. 184: 9-18.
48. Pages, G., S. Guerin, D. Grall, F. Bonino, A. Smith, F. Anjuere, P. Auberger, and J. Pouyssegur. 1999. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 286: 1374-1377.
49. Sabapathy, K., Y. Hu, T. Kallunki, M. Schreiber, J. P. David, W. Jochum, E. F. Wagner, and M. Karin. 1999. JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr. Biol. 9: 116-125.
50. Rincon, M., A. Whitmarsh, D. D. Yang, L. Weiss, B. Derijard, P. Jayaraj, R. J. Davis, and R. A. Flavell. 1998. The JNK pathway regulates the in vivo deletion of immature CD4(+)CD8(+) thymocytes. J. Exp. Med. 188: 1817-1830.
51. Sugawara, T., T. Moriguchi, E. Nishida, and Y. Takahama. 1998. Differential roles of ERK and p38 MAP kinase pathways in positive and negative selection of T lymphocytes. Immunity 9: 565-574.